Next Generation Sequencing (NGS) Market Size, Share, Growth, and Industry Analysis, By Type (Targeted Sequencing, Whole Exome Sequencing, Whole Genome Sequencing), By Application (Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals & Clinics), and by Regional Forecast to 2035

• 

  Download Free Sample to learn more about this report

NEXT GENERATION SEQUENCING (NGS) MARKET OVERVIEW

The Next Generation Sequencing (NGS) Market, value at USD 7.35 Billion in 2026 and surpass USD 15.16 Billion by 2035 expanding at a CAGR of 8% from 2026 to 2035.

The Next Generation Sequencing (NGS) market is expanding rapidly as genomic testing moves from research laboratories into hospitals, pharmaceutical development, and national screening programs. North America accounted for 45% of global demand in 2025, while targeted sequencing represented 48% of technology adoption due to lower data burden and faster clinical reporting. Academic research institutes contributed 36% of end-user utilization, reflecting strong genome center activity. Sequencing consumables and workflow services formed 64% of recurring market demand. Increasing use of oncology panels, inherited disease testing, and infectious disease surveillance continues to strengthen global instrument placements and reagent consumption.

The United States remains the largest single-country market for Next Generation Sequencing (NGS), supported by strong genomic research funding, advanced healthcare systems, and high clinical test adoption. The USA contributes more than 70% of North American sequencing demand and hosts over 200 major genomics laboratories with high-throughput capabilities. Oncology testing volumes continue to rise, with more than 60% of large cancer centers using NGS panels in routine patient management. Growing rare disease diagnosis programs and prenatal screening adoption are also driving recurring demand for sequencing kits, software, and laboratory automation systems.

KEY FINDINGS

NEXT GENERATION SEQUENCING (NGS) MARKET LATEST TRENDS

The Next Generation Sequencing (NGS) market is experiencing strong transformation through faster workflows, lower sequencing cost per sample, and wider clinical acceptance. Targeted sequencing remains the leading segment with 48% share because hospitals prefer focused panels for oncology and inherited disease testing. Oncology applications represent nearly 32% of total market usage, making cancer genomics the largest demand center for reagents and software. Academic institutions continue to represent 36% of end-user consumption, supported by translational medicine and population genetics studies.

Long-read sequencing is becoming an important trend because it improves structural variant detection and genome assembly accuracy. New systems now support average read lengths above 10,000 bases, allowing stronger repeat-region analysis. Automated sample preparation platforms have reduced manual handling steps by 25%, improving consistency and lowering contamination risk. Hospitals increasingly demand same-day or next-day results, leading to adoption of rapid library preparation kits and integrated workflow systems. Cloud-based bioinformatics is also rising because a single whole genome dataset can exceed 0.2 terabytes of raw information. AI-supported interpretation tools are helping reduce reporting times by 35% in some laboratories. Multi-omics sequencing approaches combining DNA, RNA, and methylation analysis are expanding in oncology research and precision medicine trials worldwide.

Download Free Sample to learn more about this report

SEGMENTATION ANALYSIS

The Next Generation Sequencing (NGS) market is segmented by type and application. By type, targeted sequencing leads because it offers lower data complexity and faster turnaround times. Whole exome sequencing remains preferred for rare disease and inherited disorder analysis, while whole genome sequencing is expanding for complete genomic profiling. By application, academic and government research institutes account for 36% of total demand. Pharmaceutical and biotechnology companies use NGS for biomarker discovery, therapy development, and trial enrollment. Hospitals and clinics are increasing adoption through oncology testing, prenatal diagnostics, and infectious disease detection.

By Type

• Targeted Sequencing: Targeted sequencing is the largest type segment, holding 48% of the market. It focuses on selected genes or mutation hotspots, reducing sequencing cost and shortening result timelines. Many clinical oncology panels analyze between 50 and 500 genes, making them suitable for hospital laboratories. Smaller data files reduce storage needs and simplify interpretation. Demand is especially strong in hereditary cancer testing, liquid biopsy monitoring, and solid tumor mutation profiling. Recurring reagent purchases remain high because many patients undergo repeated monitoring throughout treatment cycles.

• Whole Exome Sequencing: Whole exome sequencing captures coding regions that represent nearly 2% of the genome while containing a large proportion of disease-related variants. This makes it valuable for rare disease diagnosis and pediatric genetics. Whole exome sequencing held about 29% of type demand in 2025. Laboratories favor exome testing because it balances broad variant discovery with manageable data output. Demand is increasing in neurology, cardiology, and metabolic disease studies, where exome sequencing often shortens diagnostic timelines by several months.

• Whole Genome Sequencing: Whole genome sequencing analyzes nearly 100% of genomic content and held approximately 23% of type demand. It is expanding in newborn screening, pathogen surveillance, reproductive medicine, and advanced oncology. Whole genome sequencing detects structural variants, copy number changes, mitochondrial mutations, and noncoding alterations often missed by narrower tests. High-throughput systems can process billions of reads in one run, making large population genome projects more practical for public health institutions and research centers.

By Application

• Academic & Government Research Institutes: Academic and government research institutes represent the largest application segment with 36% share. Universities, national genome centers, and public laboratories conduct cancer biology, microbiome, agriculture, and population genetics projects using large sample cohorts. Many centers process over 10,000 samples annually, creating strong demand for consumables and data analysis software. Government grants continue supporting biobank sequencing and translational medicine programs.

• Pharmaceutical Companies: Pharmaceutical companies account for approximately 24% of application demand. NGS is used for target discovery, biomarker identification, patient stratification, and companion diagnostic development. Oncology drug trials increasingly depend on genomic matching to improve enrollment quality. Sequencing integration across Phase I, II, and III studies continues to expand, especially in immunotherapy and rare disease pipelines.

• Biotechnology Companies: Biotechnology companies hold nearly 18% of application share. They use NGS for gene editing validation, cell therapy development, vector integrity checks, and single-cell analysis. Smaller benchtop sequencers are popular among biotech firms handling moderate sample volumes. Startup innovation in liquid biopsy and synthetic biology is increasing sequencing demand across early-stage research programs.

• Hospitals & Clinics: Hospitals and clinics represent around 22% of application demand and are one of the fastest-growing user groups. NGS is increasingly used in tumor profiling, prenatal testing, neonatal intensive care, and infectious disease panels. Many healthcare centers now target result delivery within 24 to 72 hours for urgent cases. Integrated sequencing systems are helping hospitals perform in-house testing rather than relying only on external reference laboratories.

NEXT GENERATION SEQUENCING (NGS) MARKET DYNAMICS

DRIVER

Rising demand for precision medicine and oncology diagnostics

The strongest growth driver for the Next Generation Sequencing (NGS) market is precision medicine adoption. Oncology applications account for nearly 32% of total demand, supported by tumor mutation profiling and therapy selection. More than 60% of major cancer centers now use genomic panels in routine clinical pathways. Rare disease programs are another growth factor, as genome-based diagnosis reduces long periods of inconclusive testing. National genomics programs in developed economies are increasing instrument placements and long-term reagent demand.

RESTRAINT

High equipment costs and complex data interpretation

Although sequencing costs have declined, advanced instruments still require substantial capital investment and controlled laboratory infrastructure. Around 41% of smaller laboratories report difficulty hiring trained bioinformatics staff. Data interpretation remains complex because one genome run can generate large datasets requiring advanced software pipelines. Reimbursement uncertainty affects 29% of healthcare providers, slowing adoption in cost-sensitive regions.

Expansion of population genomics and decentralized testing

Opportunity

Population genomics programs create major opportunity for the Next Generation Sequencing (NGS) market. Several national initiatives involve cohorts above 100,000 participants, requiring long-term sequencing capacity. Compact sequencers are enabling decentralized testing in hospitals and regional laboratories. Prenatal screening, transplant monitoring, and antimicrobial resistance surveillance remain underpenetrated areas with strong growth potential. AI-assisted reporting tools are reducing result turnaround times by 35% in selected laboratories.

Standardization, regulation, and cybersecurity risks

Challenge

The market faces ongoing challenges in harmonizing workflows across instruments, software, and laboratories. Different library preparation methods can alter low-frequency variant detection accuracy by 15% in comparative studies. Regulatory approval timelines differ significantly across regions, slowing international product launches. Clinical genomic files contain sensitive patient data, increasing cybersecurity compliance costs. New sequencing platforms that improve throughput by 40% also create larger downstream storage and data management burdens.

• Download Free Sample to learn more about this report

•  

NEXT GENERATION SEQUENCING (NGS) MARKET REGIONAL OUTLOOK

• North America

North America remains the leading regional market for Next Generation Sequencing (NGS), holding 45% of global share. The United States contributes more than 70% of regional demand, supported by strong genomic research funding, large cancer testing networks, and advanced healthcare laboratories. More than 0.2 billion genomic tests and research samples are processed annually across public and private laboratories. High adoption of targeted sequencing panels in oncology and hereditary disease testing continues to support recurring consumable demand. Clinical diagnostics is a major growth pillar in North America. Over 60% of major cancer centers use NGS panels in routine patient treatment pathways. Whole exome sequencing adoption is rising in pediatric rare disease centers, while rapid whole genome sequencing is increasingly used in neonatal intensive care. Sequencing automation systems have improved workflow productivity by 30% in several large laboratories. Strong reimbursement pathways for selected oncology and inherited disease tests continue to support hospital adoption.

Canada also supports regional expansion through population genomics and precision medicine programs. Government-backed genome projects involving more than 0.1 billion data points have increased demand for bioinformatics platforms. Pharmaceutical companies across North America use NGS in immunotherapy trials, biomarker screening, and companion diagnostics. North America also hosts the largest installed base of high-throughput sequencers, giving the region continued leadership in instrument upgrades and software subscriptions.

• Europe

Europe holds 28% of the global Next Generation Sequencing (NGS) market and remains the second-largest region. Germany, the United Kingdom, France, Switzerland, and the Netherlands are major contributors to demand. Public healthcare systems across Europe increasingly integrate NGS into oncology, prenatal testing, and inherited disease diagnosis. More than 0.1 billion genomic samples and associated datasets are processed through academic and clinical programs each year. Strong regulatory frameworks support quality assurance and standardized testing. The United Kingdom is a leading innovation center with large national genome initiatives and hospital-based genomic medicine services. Germany remains a key market for sequencing instruments, reagents, and diagnostics software, while France has expanded cancer biomarker testing programs. European laboratories report automation-driven productivity gains of 25% in sample preparation workflows. Targeted sequencing remains the dominant technology, accounting for nearly 49% of regional technology demand.

Biopharmaceutical use of NGS is also growing across Europe. Drug developers increasingly use sequencing for patient stratification and trial enrollment in oncology and rare disease studies. Single-cell sequencing and long-read sequencing demand has increased by 22% across research institutions. Academic genome centers continue to attract funding for microbiome, agricultural genomics, and population health studies, strengthening long-term consumables demand across the region.

• Asia-Pacific

Asia-Pacific accounts for 22% of the global Next Generation Sequencing (NGS) market and is the fastest expanding region. China, Japan, South Korea, India, Singapore, and Australia are major demand centers. China leads regional instrument installations and large-scale population genomics initiatives. The region processes over 0.2 billion sequencing samples and research datasets annually, supported by rising hospital adoption and academic research growth. Domestic manufacturing of sequencing systems is also increasing. China remains a major force through large genomics enterprises, public health testing networks, and oncology diagnostics expansion. Japan leads in precision oncology and hereditary disease screening, while South Korea supports strong biotechnology demand. India is emerging as a cost-efficient sequencing hub with expanding pathology laboratory chains. Clinical sequencing test volumes across Asia-Pacific have increased by 35% in recent years due to broader awareness and lower workflow costs.

Academic institutes in Asia-Pacific continue to invest heavily in agriculture genomics, infectious disease surveillance, and stem cell research. Many laboratories are adopting benchtop sequencers for decentralized testing. Long-read sequencing demand rose 24% as structural variant research increased. Government support for genome databases, newborn screening pilots, and national biotechnology strategies will continue strengthening reagent and analytics demand across the region.

• Middle East & Africa

Middle East & Africa represents 5% of the global Next Generation Sequencing (NGS) market, with strong growth potential from a smaller base. The United Arab Emirates, Saudi Arabia, South Africa, Israel, and Egypt are major regional contributors. Precision medicine programs and hospital modernization are increasing adoption of sequencing platforms. More than 0.05 billion genomic samples, screening datasets, and research analyses are processed annually across the region. Public-private healthcare investments remain a key expansion driver. Saudi Arabia and the UAE are investing in national genomics databases and inherited disease screening due to high rates of consanguinity-linked disorders. Several leading hospitals now use NGS for oncology panels, prenatal diagnostics, and infectious disease surveillance. Laboratory workflow upgrades have improved turnaround times by 28% in selected centers. Israel remains an innovation hub with strong biotechnology research and clinical genomics expertise.

Africa is gradually increasing NGS adoption through infectious disease surveillance, agricultural genomics, and university collaborations. South Africa leads regional research sequencing capacity, while Egypt and Kenya are expanding molecular diagnostic capabilities. International funding programs continue supporting pathogen monitoring and rare disease diagnosis. Portable and lower-cost sequencing systems are expected to increase accessibility, especially in decentralized laboratories and public health settings.

List of Top Next Generation Sequencing (NGS) Companies

• Illumina [United States]
• Thermo Fisher Scientific [United States]
• Pacific Biosciences of California [United States]
• Beijing Genomics Institute (BGI) [China]
• Qiagen [Germany]
• Roche [Switzerland]
• Agilent Technologies [United States]
• PerkinElmer [United States]
• Genomatix [Germany]
• PierianDx [United States]
• Eurofins Scientific [Luxembourg]
• GATC Biotech [Germany]
• Oxford Nanopore Technologies [United Kingdom]
• Bio-Rad Laboratories [United States]
• DNASTAR [United States]
• Biomatters [New Zealand]
• Partek [United States]
• New England Biolabs [United States]
• Myriad Genetics [United States]
• Macrogen [South Korea]

List of Top 2 Companies Market Share

• Illumina: Holds approximately 52% of global NGS instrument and consumables market share, supported by dominant installed base and broad sequencing workflow portfolio.
• Thermo Fisher Scientific: Holds approximately 17% global market share through Ion Torrent platforms, reagents, and integrated genomics solutions.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Next Generation Sequencing (NGS) market continues attracting investment across instruments, consumables, software, and clinical testing services. Venture funding for genomics startups increased by 18% in recent periods, driven by AI bioinformatics, liquid biopsy, and long-read sequencing opportunities. Pharmaceutical companies allocate more than 0.1 billion annually in combined genomics partnerships for biomarker discovery and trial stratification. Sequencing consumables remain attractive because they generate recurring demand after each installed instrument placement. Clinical diagnostics presents one of the largest opportunities. Oncology sequencing demand has crossed 32% of total market usage, creating investment potential in hospital laboratory networks and companion diagnostic developers. Prenatal screening and neonatal rapid genome testing are also expanding. Automated sample preparation systems that improve productivity by 30% offer strong adoption potential in high-volume laboratories. Emerging markets are increasingly funding national genome databases and precision medicine centers.

Asia-Pacific offers major expansion potential due to rising healthcare infrastructure and domestic sequencing production. Investors are also targeting cloud analytics platforms because one whole genome dataset can exceed 0.2 terabytes, creating demand for storage and interpretation tools. Mergers, licensing agreements, and reagent manufacturing partnerships are expected to remain active as companies seek scale, installed base growth, and geographic diversification.

NEW PRODUCT DEVELOPMENT

New product development in the Next Generation Sequencing (NGS) market is focused on faster turnaround time, higher accuracy, and simplified workflows. Recent platforms have increased sample throughput by 40% while reducing run time by 30%. Instrument makers are launching compact systems for hospitals and decentralized laboratories, enabling lower batch-size sequencing. Enhanced optical systems and improved chemistry kits are also lifting base-calling accuracy above previous generation platforms. Long-read sequencing innovation is another major area. New systems now generate average reads above 10,000 bases, supporting structural variant analysis and de novo genome assembly. Portable sequencing devices are being upgraded with stronger signal processing and real-time analytics. Demand is increasing among infectious disease surveillance centers and field researchers that require rapid deployment.

Software development remains equally important. AI-based variant interpretation tools reduce report generation time by 35% and improve workflow standardization. Cloud-native platforms now integrate sample tracking, sequencing analysis, and clinician reporting in one interface. Multiplex library preparation kits are allowing laboratories to process larger sample pools per run, improving efficiency and lowering per-sample operating costs.

FIVE RECENT DEVELOPMENTS (2023-2025)

• March 2023: Illumina expanded NovaSeq X commercial rollout, offering up to 2x higher throughput efficiency compared with earlier systems.
• July 2023: Oxford Nanopore introduced upgraded flow cells with accuracy improvements above 99% for selected applications.
• February 2024: Thermo Fisher Scientific launched updated Ion Torrent workflows reducing preparation time by 25% for clinical labs.
• September 2024: Pacific Biosciences released enhanced long-read chemistry increasing average read length beyond 10,000 bases.
• January 2025: BGI expanded automated sequencing capacity in Asia with workflow productivity gains of 30% across new installations.

REPORT COVERAGE OF NEXT GENERATION SEQUENCING (NGS) MARKET

This report on the Next Generation Sequencing (NGS) market covers technology trends, regional demand, competitive positioning, and end-user adoption across global markets. It evaluates North America with 45% market share, Europe with 28%, Asia-Pacific with 22%, and Middle East & Africa with 5% share. The study includes analysis of consumables, instruments, software, and sequencing services. Clinical adoption in oncology, rare disease, and prenatal testing is a major focus area. The report also examines segmentation by technology, where targeted sequencing leads with 48% share, followed by whole exome and whole genome sequencing. Application analysis includes academic institutes, pharmaceutical companies, biotechnology firms, and hospitals. More than 36% of demand originates from research institutions, highlighting continued public and private R&D importance.

Competitive coverage includes leading manufacturers, installed base strength, product pipelines, partnership strategies, and innovation trends. The report assesses workflow automation gains of 30%, throughput improvements of 40%, and AI software adoption across laboratories. It also reviews investment opportunities in emerging markets, long-read sequencing, decentralized testing, and cloud bioinformatics platforms.